Cudarolimab
Based on 1 Customer Validation
Cudarolimab (IBI101) is a completely human anti-OX40 (CD134, a co stimulating molecule expressed by activated immune cells) antibody. Cudarolimab inhibits the binding of OX40 to its ligand OX40L. Cudarolimab has antitumor activity and can be used in cancer related research.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 95.00%
- CAS No.: 2244739-29-3
- Masse moléculaire:145.94 kDa
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
-
HY-P99945
RevdofilimabOX40 Monoclonal Antibody -
HY-139559
VornorexantOX1R/OX2R Antagonist -
HY-133898
DanavorextonOrexin Receptor Agonist -
HY-P99249
VonlerolizumabOX40 Antibody -
HY-137440
FirazorextonOX2R Agonist -
HY-152843
FazamorexantOrexin Receptor Antagonist -
HY-134188
JNJ-54717793OX1R Antagonist -
HY-137440A
Firazorexton hydrateOX2R Agonist -
HY-136181
YNT-185 dihydrochlorideOrexin Receptor 2 Agonist -
HY-147294
NivasorexantOrexin 1 Receptor Inhibitor -
HY-P99955
RocatinlimabAnti-OX40 Antibody -
HY-P99570
TelazorlimabAnti-OX40 Costimulatory Receptor Antibody
Voir tous les produits spécifiques à Isoform Orexin Receptor (OX Receptor)
More
Activité biologique
Description
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
TNFRSF4/OX40/CD134
In Vitro
Cudarolimab (0.01, 1, 100 or 10000 nM) binds to OX40 and partially blocks the binding of OX40 to its ligand OX40L in CHO-S cells overexpressing human OX40 (CHO-S-hOX40). Cudarolimab activates OX40 dependent NF-κB reporters with an EC50 value of 4.432 nM in Jurkat-OX40 reporter cells co-cultured with Raji cells[1].
Cudarolimab (0.01, 0.1, 1, 10, 100 or 1000 nM) binds to activated human CD4+ T cells and activated cynomolgus monkey CD4+ T cells in a dose dependent manner[1].
Cudarolimab (0.4, 4.0 and 40.4 nM) increases IL-2 secretion with dose dependent manner in human CD4+ T cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Cudarolimab (0.1, 1 and 10 mg/kg; i.p.; single dose on days 6, 9, 12 and 16) significantly reduces tumor volume, increases IFN-γ+ and IFN-α+ expression in CD8+ T cells in tumor and spleen of human OX40 knock-in mice bearing MC38 tumors[1].
Cudarolimab (10 mg/kg; i.p.; single dose on days 10 and 14) significantly reduces the expression of CD3+CD8+, CD3+CD4+, CD4+CD25highFoxP3+ in the tumor and spleen of human OX40 knock-in mice bearing MC38 tumors[1].
Pharmacokinetic (PK) parameters of Cudarolimab in cynomolgus macaques[1]
| Dose (mg/kg) | Cmax (µg/mL ) | Tmax (h) | AUC0-∞ (h•µg/mL ) | T1/2 (h) | Cl (mL/h/kg) | MRTlast (h) |
| 0.1 | 3.07±0.40 | 0.08±0.00 | 347.98±99.30 | 162.98±103.01 | 0.31±0.08 | 186.34±110.68 |
| 0.5 | 9.78±3.27 | 0.40±0.78 | 1429.19±607.21 | 129.47±114.44 | 0.40±0.14 | 136.03±108.05 |
| 2.5 | 63.10±15.29 | 0.08±0.00 | 10304.06±3403.59 | 190.89±92.94 | 0.27±0.09 | 212.29±114.61 |
| 12.5 | 296.57±58.05 | 0.40±0.78 | 33511.65±14982.36 | 120.30±153.26 | 0.44±0.20 | 114.93±87.66 |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Humanized NOG mice bearing LoVo tumors[1].
-
Dosage:10 mg/kg.
-
Administration:Intraperitoneal injection; single dose on days 3, 7, 11, 14 and 15.
-
Result:Reduced tumor volume.
-
Animal Model:Human OX40 knock-in mice bearing MC38 tumors[1].
-
Dosage:0.1, 1 and 10 mg/kg.
-
Administration:Intraperitoneal injection; single dose on days 6, 9, 10, 12, 14 and 16.
-
Result:Showed anti-tumor activity.
Essai clinique
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 kappa
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Flow cytometric analysis of 1X106 500 ng/mL anti-CD3 and 500 ng/mL ant-CD28 co-stimulated Jurkat cells(24h) with Cudarolimab (HY-P99836, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
Chemical Information
-
CAS No. 2244739-29-3
-
Appearance Liquid
-
Masse moléculaire 145.94 kDa
-
Color Colorless to light yellow
-
SMILES
[Cudarolimab]
-
Synonyms
IBI101
-
Livraison
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
-
Fiche technique (262 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Cudarolimab Related Classifications
HY-P99836 Related Classifications
Powered by Bioz